Ticagrelor, sold under the brand name Brilinta among others, is a medication used for the prevention of stroke, heart attack and other events in people with acute coronary syndrome, meaning problems with blood supply in the coronary arteries. It acts as a platelet aggregation inhibitor by antagonising the P2Y12 receptor.[7] The drug is produced by AstraZeneca.
90 mg tablet of Brilinta
The most common side effects include dyspnea (difficulty breathing), bleeding and raised uric acid level in the blood.[6]
It was approved for medical use in the European Union in December 2010,[6][8][9] and in the United States in July 2011.[5][10][11] In 2020, it was the 247th most commonly prescribed medication in the United States, with more than 1million prescriptions.[12][13]
^"Updates to the Prescribing Medicines in Pregnancy database". Therapeutic Goods Administration (TGA). 12 May 2022. Retrieved 13 May 2022.
^"FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.
^"Ticalor; Blooms The Chemist Ticagrelor; Apo-Ticagrelor; Ticagrelor Arx (Accelagen Pty Ltd)". Therapeutic Goods Administration (TGA). 11 November 2022. Retrieved 9 April 2023.
^"Product monograph brand safety updates". Health Canada. February 2024. Retrieved 24 March 2024.
^ ab"Brilinta- ticagrelor tablet". DailyMed. 10 August 2021. Retrieved 19 May 2022.
^ abc"Brilique EPAR". European Medicines Agency. 17 September 2018. Retrieved 18 May 2022. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
^Jacobson KA, Boeynaems JM (July 2010). "P2Y nucleotide receptors: promise of therapeutic applications". Drug Discovery Today. 15 (13–14): 570–578. doi:10.1016/j.drudis.2010.05.011. PMC 2920619. PMID 20594935.
^"Assessment Report for Brilique" (PDF). European Medicines Agency. January 2011.
^European Public Assessment Report Possia
^"FDA approves blood-thinning drug Brilinta to treat acute coronary syndromes" (Press release). U.S. Food and Drug Administration (FDA). 20 July 2011. Archived from the original on 12 January 2017.
^"Drug Approval Package: Brilinta (ticagrelor) NDA #022433". U.S. Food and Drug Administration (FDA). 22 August 2011. Retrieved 22 May 2021.
^"The Top 300 of 2020". ClinCalc. Retrieved 7 October 2022.
^"Ticagrelor - Drug Usage Statistics". ClinCalc. Retrieved 7 October 2022.
Ticagrelor, sold under the brand name Brilinta among others, is a medication used for the prevention of stroke, heart attack and other events in people...
neuroprotection. The drugs clopidogrel (Plavix), prasugrel (Efient, Effient), ticagrelor (Brilinta), and cangrelor (Kengreal) bind to this receptor and are marketed...
in-vivo to inhibit the P2Y12 receptor. On the other hand, novel drugs like ticagrelor (Brilinta®) and cangrelor (Kengrexal®) are non-thienopyridines and reversibly...
of aspirin plus an ADP/P2Y inhibitor (such as clopidogrel, prasugrel, ticagrelor, or another) is used to obtain greater effectiveness than with either...
indefinitely, as well as another antiplatelet agent such as clopidogrel or ticagrelor ("dual antiplatelet therapy" or DAPT) for up to twelve months. If someone...
order to avoid confusion with the blood-thinning medication Brilinta (ticagrelor). Other brand names include Vantaxa, Torvox, Voxigain, Trivoxetin, Trintellix...
trials to function as a reversal agent for the anti–blood clotting drug ticagrelor (which acts as a P2Y12 inhibitor and is sold under the brand name Brilinta...
advent of newer and safer antiplatelet drugs such as clopidogrel and ticagrelor, its use remained limited. It was patented in 1973 and approved for medical...
medications: cisapride, pimozide, astemizole, terfenadine, ergotamine, ticagrelor, ranolazine or dihydroergotamine is not recommended. It should not be...
assessing cangrelor administration in conjunction with either prasugrel or ticagrelor. Cangrelor been approved for adults undergoing percutaneous coronary intervention...
with presumed ACS are typically treated with aspirin, clopidogrel or ticagrelor, nitroglycerin, and if the chest discomfort persists morphine. Other analgesics...
ticlopidine (Ticlid). Tinoridine was actually a predecessor to this work. Ticagrelor (Brilinta) is often listed with thienopyridine inhibitors and has similar...
Anti-platelet agents include aspirin, dipyridamole, ticlopidine, clopidogrel, ticagrelor and prasugrel; the parenteral glycoprotein IIb/IIIa inhibitors are used...
2021 a higher risk of stroke at 90 days was found with clopidogrel than ticagrelor, which does not require metabolic conversion, among Han Chinese CYP2C19...
Global Information
(what is this?) (verify)
